XTX Topco在混杂信号中购买了Celldex股份:内幕销售、季度亏损和“Moderate Buy”评级。 XTX Topco bought Celldex shares amid mixed signals: insider selling, a quarterly loss, and a "Moderate Buy" rating.

XTX Topco有限公司在第二季度以约372 000美元购买了18 291份Celdex治疗设备(CLDX)的股份。 XTX Topco Ltd acquired 18,291 shares of Celldex Therapeutics (CLDX) for about $372,000 in the second quarter. 该公司报告季度每股损失1.01美元,估计损失0.88美元,净差为-3446.88%,股本回报为负值。 The company reported a quarterly loss of $1.01 per share, missing estimates of $0.88, with a net margin of -3,446.88% and negative return on equity. 该股票于2025年12月6日以2.945美元关闭,接近52周的最高点29.83美元,市场上限为19.6亿美元。 The stock closed at $29.45 on December 6, 2025, near its 52-week high of $29.83, with a market cap of $1.96 billion. Geode Capital Management的股份增加了83 174股。 Geode Capital Management increased its stake by 83,174 shares. 内幕Richard M. Wright以24.00美元出售了49 298股股票,其所有权减少了70.29%。 Insider Richard M. Wright sold 49,298 shares at $24.00, reducing his ownership by 70.29%. 内部人员集体拥有公司4.40%的股份。 Insiders collectively own 4.40% of the company. 分析师将该股票评为"中等买入",目标价为43.80美元. Analysts rate the stock a “Moderate Buy” with a $43.80 target. Celldex研制出单克隆和双克隆抗体来治疗严重疾病。 Celldex develops monoclonal and bispecific antibodies for serious diseases.